Exact Sciences shares slid -3.0% this afternoon. Here's what you need to know about the Mid-CapMedical specialities company:
-
Exact Sciences has logged a -39.7% 52 week change, compared to 26.5% for the S&P 500
-
EXAS has an average analyst rating of buy and is -41.9% away from its mean target price of $86.71 per share
-
Its trailing earnings per share (EPS) is $-1.31, which brings its trailing Price to Earnings (P/E) ratio to -38.5. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $-0.08 and its forward P/E ratio is -629.8
-
The company has a Price to Book (P/B) ratio of 2.96 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 2.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $31.93 Million and the average free cash flow growth rate is 2.4%
-
Exact Sciences's revenues have an average growth rate of 30.3% with operating expenses growing at 28.3%. The company's current operating margins stand at -8.6%